ABSTRACT
Gonadotropin releasing hormone (GnRH) analog agonists have acquired an important place in in vitro fertilization (IVF) treatments. They owe their popularity on the one hand to their ability to down-regulate luteinizing hormone (LH), thereby preventing premature luteinization, and on the other hand to the fact that the effects of follicular dominance as such can be obviated in contrast to gonadotropin-only protocols. We should still remain cautious, however, with regard to the exclusive use of these compounds in ovarian stimulation, and one should wonder whether the features that make these compounds so popular are sufficient justification for the widespread use of them as a first choice.
